You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,521,815


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,521,815
Title: Animal model system for squamous cell carcinoma
Abstract:Non-human mammalian animals having a higher epidermal expression level of protein kinase C.epsilon. than their wild-type counterparts are phenotypically distinguished from wild-type animals in that the animals induced to develop tumors in a chemical initiation/promotion protocol are suppressed for subsequent papilloma development but are susceptible to developing squamous cell carcinoma and metastatic squamous cell carcinoma. The animals are advantageously used in methods for screening putative agents for altering the susceptibility, development and progression of squamous cell carcinoma and metastatic squamous cell carcinoma and have further commercial value as tools for investigating the development of metastatic disease.
Inventor(s): Verma; Ajit K. (Madison, WI), Reddig; Peter J. (Durham, NC), Jansen; Aaron P. (New Market, MD)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:09/772,647
Patent Claims:1. A genetically modified FVB/N mouse having epidermal cells that comprise a protein kinase C.epsilon. activity higher than that of wild-type FVB/N epidermal cells.

2. An FVB/N mouse as claimed in claim 1 wherein the protein kinase C.epsilon. level is at least 5-fold higher than that of wild-type FVB/N epidermal cells.

3. An FVB/N mouse as claimed in claim 1 wherein the protein kinase C.epsilon. level is at least 12-fold higher than that of wild-type FVB/N epidermal cells.

4. An FVB/N mouse as claimed in claim 1 wherein the protein kinase C.epsilon. level is at least 15-fold higher than that of wild-type FVB/N epidermal cells.

5. An FVB/N mouse as claimed in claim 1 wherein the protein kinase C.epsilon. level is at least 18-fold higher than that of wild-type FVB/N epidermal cells.

6. An FVB/N mouse as claimed in claim 1 wherein the mouse exhibits metastatic squamous cell carcinoma disease.

7. An FVB/N mouse as claimed in claim 1 comprising in the epidermal cells a transgene that comprises a polynucleotide that encodes Protein Kinase C.epsilon. under the transcriptional control of an upstream promoter active in keratinocytes and a downstream polyA addition sequence.

8. An FVB/N mouse as claimed in claim 7 wherein the upstream promoter is a keratin promoter.

9. An FVB/N mouse as claimed in claim 8 wherein the upstream promoter is a K14 promoter.

10. An FVB/N mouse as claimed in claim 7 further comprising a transcription enhancing element.

11. An FVB/N mouse as claimed in claim 10 wherein the transcription enhancing element is a .beta.-globin intron sequence.

12. An FVB/N mouse as claimed in claim 7 wherein the transgene comprises SEQ ID NO:3.

13. A transgenic mouse whose somatic and germ cells contain a chimeric DNA sequence comprising a keratin promoter/regulatory sequence operably linked to a sequence encoding protein kinase C.epsilon., wherein epidermal expression of said protein kinase C.epsilon. results in a phenotype selected from the group consisting of inflammation, hyperkeratosis, hyperplasia, cellular hypertrophy, and ulceration.

14. An FVB/N mouse as claimed in claim 1 wherein the mouse is suppressed for papilloma production and susceptible to developing squamous cell carcinoma after tumor in initiation and promotion.

15. An FVB/N mouse as claimed in claim 14 wherein the mouse is further susceptible to developing metastatic squamous cell carcinoma after tumor initiation and promotion.

16. A method for inducing squamous cell carcinoma in an FVB/N mouse suppressed for formation of papillomas, the method comprising the steps of: treating an FVB/N mouse having epidermal cells that comprise a protein kinase C.epsilon. activity higher than that of wild-type FVB/N epidermal cells with a tumor initiating agent; and treating the initiated mouse repeatedly with a tumor promoting agent until the mouse develops squamous cell carcinoma while suppressing formation of papillomas.

17. A method as claimed in claim 16 wherein the tumor initiating agent is 7,12-dimethylbenz[a]anthracene and the tumor promoting agent is 12-O-tetradecanoylphorbol-13-acetate.

18. A method as claimed in claim 16 wherein the protein kinase C.epsilon. activity is at least 12-fold higher than that of wild-type FVB/N epidermal cells and wherein the squamous cell carcinoma is metastatic.

19. A method as claimed in claim 18 wherein the protein kinase C.epsilon. activity is at least 15-fold higher than that of wild-type FVB/N epidermal cells.

20. A method as claimed in claim 18 wherein the protein kinase C.epsilon. activity is at least 18-fold higher than that of wild-type FVB/N epidermal cells.

21. A method as claimed in claim 16 wherein the epidermal cells of the FVB/N mouse comprise a polynucleotide that encodes Protein Kinase C.epsilon. under the transcriptional control of an upstream promoter active in keratinocytes and a downstream polyA addition sequence.

22. A method for evaluating effectiveness of a putative agent as a chemopreventative against squamous cell carcinoma disease in a mammal, the method comprising the steps of: administering at least one putative agent to papilloma-suppressed FVB/N mice having epidermal cells that comprise a protein kinase C.epsilon. activity higher than that of wild-type FVB/N epidermal cells, wherein the mice are susceptible to squamous cell carcinoma disease after tumor initiation and promotion, and wherein the agent is administered in an amount effective to prevent onset of the disease; treating the mice with a tumor initiating agent; and treating the initiated mice repeatedly with a tumor promoting agent evaluating the effectiveness of the at least one putative agent; and selecting from the at least one putative agent an effective chemopreventative agent.

Details for Patent 6,521,815

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.